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ABSTRACT:
The disposition of veliparib [(R)-2-(2-methylpyrrolidin-2-yl)-1H-
benzo[d]imidazole-4-carboxamide, ABT-888], a novel and potent
inhibitor of poly(ADP-ribose) polymerase for the treatment of can-
cers, was investigated in rats and dogs after intravenous and oral
administration of [3H]veliparib and compared with that of humans.
Veliparib absorption was high. Dosed radioactivity was widely dis-
tributed in rat tissues. The majority of drug-related material was
excreted in urine as unchanged drug (approximately 54, 41, and
70% of the dose in rats, dogs, and humans, respectively). A lactam
M8 and an amino acid M3 were two major excretory metabolites in
animals. In the circulation of animals and humans, veliparib was
the major drug-related component, and M8 was one of the major
metabolites. Monooxygenated metabolite M2 was significant in the
rat and dog, and M3 was also significant in the dog. Veliparib
biotransformation occurred on the pyrrolidine moiety via formation
of a lactam, an amino acid, and an N-carbamoyl glucuronide, in
addition to oxidation on benzoimidazole carboxamide and sequen-
tial glucuronidation. In vitro experiments using recombinant hu-
man cytochrome P450 (P450) enzymes identified CYP2D6 as the
major enzyme metabolizing veliparib with minor contributions from
CYP1A2, 2C19, and 3A4. Veliparib did not inhibit or induce the
activities of major human P450s. Veliparib was a weak P-glycopro-
tein (P-gp) substrate, showing no P-gp inhibition. Taken together,
these studies indicate a low potential for veliparib to cause clini-
cally significant P-gp or P450-mediated drug-drug interactions
(DDIs). Overall, the favorable dispositional and DDI profiles of ve-
liparib should be beneficial to its safety and efficacy.
Introduction
Cancer is the second leading cause of death in the United States,
contributing to 23.2% of all deaths (562,875 deaths) in 2007 (Xu et
al., 2010). It is estimated that 1,529,560 new cases of cancer will be
diagnosed and 569,490 Americans will die of cancer in 2010 (Amer-
ican Cancer Society, 2010). Increased knowledge about the disease
and its causes has resulted in identification of numerous new targets
for potential anticancer therapies. Inhibition of poly(ADP-ribose)
polymerase (PARP) has been shown to be a promising novel mech-
anism through targeting DNA repair. PARPs are a family of 17
enzymes that catalyze the transfer of ADP-ribose units to acceptor
proteins to form ADP-ribose polymer, which is involved in multiple
cellular processes such as replication, transcription, and differentia-
tion. PARP-1 is activated by DNA damage and is primarily respon-
sible for initiating the repair of single-strand DNA breaks via a base
excision repair (BER) pathway. When coadministered with DNA-
damaging chemotherapeutic agents, PARP inhibitors could potentiate
the efficacy of these agents by preventing the repair of the damaged
DNA through BER (Papeo et al., 2009; Rouleau et al., 2010). Thus,
PARP inhibitors could be developed as chemosensitizers of DNA-
damaging agents. PARP inhibitors have also demonstrated single
agent effects in selected genetic backgrounds such as tumors with
defects in the breast cancer-associated genes (BRCA-1 and -2), the
homologous recombination DNA repair regulators. PARP inhibition
blocks the BER pathway and results in “synthetic lethality” effects
toward homologous recombination-deficient tumors (Papeo et al.,
2009; Rouleau et al., 2010).
In addition to veliparib, several other PARP inhibitors are currently
in various stages of clinical development, including iniparib, olaparib,
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PF-1367338, MK-4827, and CEP-9722 (Penning, 2010). These agents
are being developed as chemopotentiators of DNA-damaging chemo-
therapeutics for treatment of solid tumors (e.g., melanoma and gli-
oma) and as single agents in BRCA-deficient breast or ovarian can-
cers. Efficacy and safety data from phase I and II trials demonstrated
that PARP inhibitors in combination of cytotoxic agents were well
tolerated and showed antitumor activity (Penning, 2010).
Veliparib [(R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-
4-carboxamide, ABT-888] (Fig. 1) is a novel and potent inhibitor of
PARP-1 and PARP-2 enzymes (Ki of 5 and 2 nM, respectively) and
has demonstrated excellent in vivo efficacy in a broad spectrum of
preclinical tumor models in combination with a variety of cytotoxic
agents such as temozolomide (TMZ), cisplatin, cyclophosphamide,
and radiation (Donawho et al., 2007; Palma et al., 2009; Penning et
al., 2009). Preclinical pharmacokinetic profiles of veliparib were
characterized by high plasma clearance, high volumes of distribution,
and high oral bioavailability across species (Donawho et al., 2007). A
phase 0 clinical study of veliparib showed the statistically significant
inhibition of PARP activity in tumor biopsy specimens and peripheral
blood mononuclear cells at a single oral dose of 25 or 50 mg (Kummar
et al., 2009). The preliminary human pharmacokinetic profile was
characterized by rapid absorption (Tmax 0.5–1.5 h postdose) and
primary urinary excretion (on average, 70% of dose in urine as
unchanged parent drug at the 50-mg dose) (Kummar et al., 2009). In
patients receiving veliparib, the lactam metabolite M8 was shown to
be a major human plasma metabolite (Wiegand et al., 2010). Prelim-
inary phase I study results for veliparib in combination with TMZ in
patients with solid tumors indicated that the treatment was well
tolerated and demonstrated antitumor activity (Molina et al., 2009). At
present, veliparib is being investigated in multiple clinical trials for
human cancers either in combination with cytotoxic agents or as a
monotherapy (http://www.clinicaltrials.gov).
The objectives of the current study were as follows: 1) to charac-
terize disposition of veliparib in rats and dogs, two animal species
used for safety assessment; 2) to elucidate the structures of veliparib
metabolites; 3) to characterize the interactions of veliparib with hu-
man P-glycoprotein (P-gp) and assess P-gp-mediated drug-drug inter-
actions (DDIs); and 4) to conduct in vitro assessment of DDIs medi-
ated by cytochrome P450 (P450) enzymes.
Materials and Methods
Materials. Veliparib and its lactam metabolite (M8) were synthesized as
described previously (Penning et al., 2009). [3H]Veliparib was synthesized by
the Radiochemistry Group, Process Research and Development, Abbott Lab-
oratories (Abbott Park, Illinois). The specific activity of [3H]veliparib was 3.2
Ci/mmol and radioactivity purity was greater than 99%. All chemicals were of
analytical grade and were purchased from Sigma-Aldrich (St. Louis, MO).
Chromatography-grade solvents were supplied by EMD Chemicals
(Gibbstown, NJ) or Sigma-Aldrich. Supersomes were purchased from BD
Gentest (Woburn, MA).
Animal Studies. Animal studies were conducted in accordance with the
guidance established by the Abbott Institutional Animal Care and Use Com-
mittees. [3H]Veliparib and nonradiolabeled veliparib were dissolved in a
mixture of ethanol and 5% dextrose in water (10:90, v/v) to make a dosing
solution at a final concentration of 5 mg/ml. The dose volume was 1.0 ml/kg
for rats and 0.5 ml/kg for dogs for both intravenous and oral dosing. The dosed
radioactivity was approximately 160 Ci/rat and 340 Ci/dog. Pre- and
postdosing radioactivity purities of the dose solutions were greater than 99%.
Dosing of [3H]Veliparib to Rats. Male Sprague-Dawley rats (220–300 g),
age 8 to 12 weeks, were used in the studies. For bile collection, six surgically
modified animals with cannulas inserted into both bile duct and duodenum
(Hilltop Laboratory Animals, Inc., Scottsdale, PA) were acclimated for ap-
proximately 4 days before dose administration. The rats were housed individ-
ually in metabolism cages and fasted overnight before dosing. Food was
provided 4 h after dosing. On the day of dosing, the biliary and duodenal
cannulas were disconnected, and a solution of taurocholic acid (27.8 mg/ml)
was infused through the duodenal cannula. Groups of three rats each received
a single 5 mg/kg intravenous dose of [3H]veliparib via the superficial penile
vein or a 5 mg/kg oral dose of [3H]veliparib. Isoflurane was used as anesthesia
during the procedure. Bile, urine, and feces were collected at the following
collection intervals: 0 to 6, 6 to 24, 24 to 48, and 48 to 72 h for bile and 0 to
24, 24 to 48, and 48 to 72 h for urine and feces. The cages were washed at the
end of the study with a small amount of 70% ethanol in water, and the cage
wash was collected for determination of total radioactivity. To obtain plasma
samples for metabolite identification and profiling, a group of three surgically
modified rats with femoral artery cannulas from Hilltop Laboratory Animals,
Inc. was given a single 5 mg/kg intravenous dose of [3H]veliparib via the
superficial penile vein. Serial blood samples (0.5 ml at each time point) were
taken via a Culex automated blood sampling system (BASi, West Lafayette,
IN) from individual rats at 0.5, 1, 2, 4, 6, and 24 h postdose. Blood samples
were centrifuged at 3000 rpm and 4°C to separate plasma (Jouan CR3 centri-
fuge, rotor model T40; Thermo Fisher Scientific, Waltham, MA), which were
stored at 20°C until analysis.
To investigate tissue distribution of [3H]veliparib, 14 rats were given a 5
mg/kg i.v. dose of [3H]veliparib via the superficial penile vein. Subgroups of
two rats were euthanized at 0.5, 1, 2, 4, 6, 24, and 48 h for collection of blood
and selected tissues (bone, bone marrow, brain, eye, heart, kidney, liver, lung,
muscle, skin, spleen, spinal cord, testes, thymus, and white fat). Blood samples
were withdrawn via cardiac puncture into heparinized tubes using Vacutainers
(BD, Franklin Lakes, NJ). Plasma samples were separated from blood by
centrifugation.
Dosing of [3H]Veliparib to Dogs. Two male beagle dogs (10–11 kg), age
2 to 2.5 years, were obtained from Marshall Research Animals (North Rose,
NY) and surgically prepared at Abbott with cannulas inserted into the bile duct
and duodenum. One single dog received a 2.5 mg/kg i.v. or p.o. dose of
[3H]veliparib. Bile, urine, and feces were collected at the same intervals as
those in rats. The cages were washed daily, and the cage wash was collected
for determination of total radioactivity. Serial blood samples (5 ml at each time
point) were taken from individual dog at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 24, and 48 h
postdose. Blood samples were centrifuged to separate plasma, which was then
stored at 20°C until analysis.
In Vitro Incubations with Recombinant Human P450s (Supersomes).
The in vitro metabolism of [3H]veliparib was investigated with a panel of
recombinant human P450 isoforms, including CYP1A1, 1A2, 2A6, 2B6, 2C8,
2C9*1, 2C18, 2C19, 2D6*1, 3A4, 3A5, and 2E1. An incubation mixture (150
l) contained individual protein (100 pmol/ml) and [3H]veliparib (0.5 M) in
50 mM potassium phosphate buffer at pH 7.4. The reaction was initiated by
addition of 1 mM NADPH and incubated at 37°C for 60 min. The reaction was
terminated by addition of 1 volume of solution of acetonitrile-methanol (50:50,
v/v). After vortexing and centrifugation, the supernatant was analyzed by
high-performance liquid chromatography (HPLC) analysis with radioactivity
detection. To identify metabolites, [3H]veliparib (10 M) was incubated with
CYP1A1, 2C19, 2D6*1, or 3A4 (100 pmol/ml) at 37°C for 60 min. TheFIG. 1. Structure of [3H]veliparib. T denotes the site of tritium labeling.
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processed samples were analyzed by HPLC-MS/MS with radioactivity detec-
tion, as described below.
Analytical Methods. Determination of total radioactivity. Total radioac-
tivity in plasma, bile, urine, and cage wash was determined in Insta-Gel Plus
(PerkinElmer Life and Analytical Sciences, Waltham, MA) scintillation cock-
tail by liquid scintillation counting (LSC) on a model 3100TR QuantaSmart
Liquid Scintillation Counter (Packard Instrument). Total radioactivity in feces
and blood was determined by LSC after sample combustion. Blood aliquots
were accurately weighed in Combusto-Cones containing Combusto-Pads and
burned in a Tri-Carb model 307 sample oxidizer (Packard Instrument). After
mixing the combusted residue with 10 ml of Monophase (Packard Instrument),
total radioactivity was determined by LSC. Feces were sufficiently covered in
70% ethanol in water, followed by homogenization with a high-frequency
homogenizer (Omni GLH-1; Omni International, Kennesaw, GA) before sam-
ple combustion.
Total radioactivity in tissue homogenates was determined by LSC after sample
solubilization. Tissues except for bone were homogenized in 70% ethanol in water.
The exact weight of the homogenate was recorded. Duplicate aliquots of homog-
enate or bone were accurately weighed in scintillation vials in combination with a
sufficient volume (approximately 0.5–2.0 ml) of 1 N sodium hydroxide to digest
the sample. Samples were placed in an incubator (Thelco model 6DM; Precision
Scientific, Winchester, VA) at approximately 40°C overnight or until dissolved.
After digestion, 10 ml of Insta-Gel Plus scintillation cocktail was added, and total
radioactivity was determined by LSC.
Final radioactivity concentrations were determined from the specific activ-
ity of the dose solution using DEBRA data management software (version
5.7.6.100; LabLogic Systems Ltd., Sheffield, UK).
Processing of animal samples for metabolite identification and profiling. Rat
plasma (90 l) was pooled from three rats at each time point. Pooled samples were
extracted with 4 volumes of acetonitrile-methanol (50:50, v/v), followed by
vortexing and centrifugation at 3000 rpm at 4°C for 30 min using a Eppendorf
5810R centrifuge (rotor model A4-81; Eppendorf AG, Hamburg, Germany).
Supernatants were concentrated in a Savant SpeedVac (Thermo Fisher Scientific)
for 4.5 h. The residue was reconstituted in 100 l of methanol-water (50:50, v/v)
before HPLC-MS/MS analysis. Dog plasma (1–2 ml) at each time point was
sequentially extracted with 5 and 8 ml of acetonitrile-methanol (50:50, v/v). After
vortexing and centrifugation, the supernatants were concentrated by SpeedVac
overnight, and the residue was reconstituted in 180 to 240 l of methanol-water
(50:50, v/v) before HPLC-MS/MS analysis.
Rat urine or bile samples were pooled at equal percent weight from each
animal, followed by centrifugation. Supernatants were transferred to vials with
inserts for HPLC-MS/MS analysis. Aliquots of individual dog urine and bile
samples were filtered before HPLC-MS/MS analysis.
HPLC-MS/MS analysis with radioactivity detection. Veliparib and its me-
tabolites were identified and profiled in in vitro or in vivo studies after
separation by HPLC and detection by an on-line or off-line radiochemical
detector coupled with a mass spectrometer. The HPLC system consisted of an
Agilent 1100 series binary pump and an Agilent 1100 series autosampler
(Agilent Technologies, Santa Clara, CA). Metabolites were eluted at room
temperature on a Luna C18, 5 m, 100 Å, 150  4.6 mm i.d. HPLC column
(Phenomenex, Torrance, CA). The mobile phases consisted of 10 mM ammo-
nium acetate in water at pH 4.0 (adjusted with acetic acid) (solvent A) and
acetonitrile (solvent B). A gradient was applied, consisting of 0% B held for 10
min, followed by a linear gradient to 15% B over the next 30 min before a
linear increase to 100% B in 5 min. The gradient was held constant at 100%
B for 5 min before returning to the initial condition of 0% B in 1 min. The
column was equilibrated at 0% B for 9 min before the next injection. The flow
rate was maintained at 1.0 ml/min.
For on-line radioactivity detection (rat urine and bile and dog urine), a flow
scintillation detector equipped with a 500-l liquid cell was used (-RAM
model 5; IN/US, Tampa, FL) with the scintillant (Flo-Scint III; PerkinElmer
Life and Analytical Sciences) flow of 2.4 ml/min. Data were processed using
Laura Light software (version 4.0.5.130; LabLogic, Broomhill, Sheffield, UK).
For off-line radioactivity detection (rat plasma and dog bile and plasma), the
HPLC effluent was collected into a 96-deep well LumaPlate (PerkinElmer Life
and Analytical Sciences) using a fraction collector (model FC 204; Gilson,
Inc., Middleton, WI) with a collection time of 3.0 s/well. The collected
fractions were dried by SpeedVac and then counted on a TopCount micro-
plate scintillation counter (PerkinElmer Life and Analytical Sciences).
Radioactivity profiles were reconstituted by ProFSA software (version
3.4.3.366; PerkinElmer Life and Analytical Sciences).
Two MS instruments were used for metabolite characterization. 1) An
LTQ-XL ion trap mass spectrometer (Thermo Fisher Scientific), equipped with
an electrospray source operated in the positive ionization mode, was used for
metabolite identification of rat urine and bile, all dog samples, and in vitro
samples. Key MS operating/acquisition parameters were as follows: source
voltage, 5 kV; capillary temperature, 275°C; capillary voltage, 25 V; and tube
lens offset, 135 V. 2) An LTQ-Orbitrap mass spectrometer (Thermo Fisher
Scientific), equipped with an electrospray source operated in the positive
ionization mode, was used for analysis of rat plasma, and to obtain high
resolution mass for all metabolites with a resolution of 30,000. All measured
metabolite masses were within 1 millimass unit of calculated masses for the
proposed metabolite structures. Key MS operating/acquisition parameters were
as follows: source voltage, 4 kV; capillary temperature, 350°C; capillary
voltage, 47 V; and tube lens offset, 35 V. The HPLC effluent was split with a
ratio of 2:8 between the mass spectrometer and an on-line radioactivity
detector or a fraction collector for off-line radioactivity detection.
Isolation of M3 from dog urine for NMR analysis. From the 0 to 24 h urine
collected from one dog, M3 was isolated using the aforementioned HPLC
system. The purified M3 was desalted on an Oasis HLB solid-phase extraction
cartridge (Waters, Milford, MA) and then dissolved in D2O for NMR analysis.
1D and 2D NMR experiments were conducted on a Varian Inova 500 MHz
NMR spectrometer (Agilent Technologies) equipped with a SMIDG500
1.7-mm indirect detection gradient probe at the Abbott Structure Chemistry
Group (Abbott Park, IL).
Interactions of Veliparib with Human P-gp. Transport of veliparib in
multidrug resistance protein 1-Madin-Darby canine kidney cells. A bidirec-
tional permeability assay of veliparib (1 M) was performed in both multidrug
resistance protein 1 (MDR1)-Madin-Darby canine kidney (MDCK) and wild-
type MDCK cell monolayers in triplicate. MDR1-MDCK and wild-type
MDCK cells were grown to confluence for 5 to 10 days on 1-m BD Falcon
filters in 24-well plates. The donor solution contained 10 M veliparib in
Hanks’ balanced salt solution (HBSS) (pH 7.4) with 0.5 mg/ml Lucifer yellow
and was supplemented with 25 mM HEPES (pH 7.4). The donor solutions
were transferred to either the apical (Ap) or basolateral (Bl) chamber of the
permeability diffusion apparatus. Receiver chambers contained 4% bovine
serum albumin in HBSS supplemented with 25 mM HEPES. Sequential
samples of transported solute were taken at 20-min intervals using an auto-
mated liquid handling platform. The concentration of transported solute during
each sampling interval was determined by HPLC-UV-MS (an Alliance 2795
HPLC system coupled with a Quattro Premier mass spectrometer; Waters).
Permeability coefficients were calculated for each sampling interval using the
following equation:
Papp, i  VD/A  1/MD0  MRt/t ith interval
where VD is volume of donor, A is the surface area of the filter on which the
monolayer was grown (square centimeters), MD(0) is the mass in the donor at
the beginning of the tth sampling interval, MR(t) is the mass in the receiver at
time t, and t is the experimental interval. The apparent permeability, Papp, is
then calculated as the average:
Papp  Papp, 1  Papp, 2  . . . Papp, n/n
The efflux ratio is defined as the ratio of apparent permeability between
basolateral-to-apical and apical-to-basolateral directions. The net flux ratio is
calculated as the ratio of the efflux ratio in MDR1-MDCK cells to the efflux
ratio in wild-type MDCK cells. The integrity of cell monolayers was evaluated
by measuring the amount of Lucifer yellow in the receiver chambers at the end
of the whole incubation period.
Inhibition of P-gp by veliparib. The inhibition potential of veliparib (0–
1000 M) on the activity of human P-gp was evaluated in duplicate in the
monolayer of Caco-2 cells (DKFZ, Heidelberg, Germany) using digoxin as the
probe substrate. Caco-2 cells were grown on Transwell HTS polycarbonate
filters (0.4-m pore, 24-well format; Corning, Inc., Corning, NY) for 22 days
before the experiment. For transport studies, cells were rinsed, preincubated in
HBSS for 30 min, and further incubated for 60 min with HBSS containing the
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designated concentration of veliparib on both sides. Cell monolayers were then
dosed with designated concentrations of veliparib and 10 M digoxin in HBSS
containing 0.5 mg/ml Lucifer yellow to either the apical or basolateral side of
the filters. Aliquots were collected at 0 and 120 min from the donor side and
at 30 and 120 min from the receiver side. Digoxin was extracted from the
aliquots with cold ethanol containing ketoprofen as internal standard for
positive ion mode and chlorzoxazone for negative ion mode. Extracted digoxin
was quantitated by liquid chromatography-MS/MS with an Agilent 1100 series
HPLC system (Agilent Technologies) coupled with a AB Sciex 5000 mass
spectrometry (Applied Biosystems/MDS Sciex, Foster City, CA). All proce-
dures were done in a tissue culture incubator (Cytomat 2C450S; Thermo Fisher
Scientific) maintained at 37°C with 5% CO2. The Ap-to-Bl and Bl-to-Ap
permeabilities (Papp) of digoxin and efflux ratios were calculated using the
aforementioned methods.
Results
In Vitro Metabolism. The in vitro metabolism of [3H]veliparib
was studied in various hepatic systems across species, including liver
S9 fractions and liver microsomes and hepatocytes from mouse, rat,
monkey, dog, and human. [3H]Veliparib was stable (	5% metabo-
lism) in all in vitro hepatic systems tested (data not shown). Using a
panel of recombinant human P450 enzymes, metabolism of [3H]ve-
liparib was observed in incubations with CYP3A4, 2C19, 1A2, and
2D6*1 with turnover of 2.0, 3.4, 8.3, and 20.6%, respectively. Mono-
oxygenation metabolite M2 was identified as the major metabolite,
and the lactam M8 was also detected in these incubations.
Structure Characterization of Veliparib Metabolites. Structures
of veliparib and its metabolites were elucidated by liquid chromatog-
raphy-MS/MS using a combination of full-scan and product ion scan
(MS2 or MS3) analyses of biological samples. The structure of M8
was supported by comparisons of its HPLC retention time and mass
spectrum with those of a synthetic standard. The structure of M3 was
characterized by 1D and 2D NMR analysis. Structures of all other
metabolites are proposed on the basis of high-resolution mass and
MS2 fragmentation analysis.
Veliparib. Parent drug veliparib eluted at 
28 min on HPLC
analysis, displaying a protonated molecular ion at m/z 245. MS/MS
fragment ions at m/z 162 and 84 indicated the cleavage between
benzoimidazole carboxamide and 2-methylpyrrolidine. The fragment
ion at m/z 145 resulted from loss of NH3 from the ion of m/z 162.
M1 and M2. Two metabolites (M1 and M2) with same protonated
molecular ion of m/z 261 were observed in urine and plasma from rat
and dog eluting at approximately 26 and 27 min, respectively, by
HPLC analysis. High-resolution MS analysis suggested addition of
one oxygen atom (16 amu) to veliparib. MS/MS analysis of M1
showed fragment ions at m/z 162 and 100, suggesting oxygenation on
2-methylpyrrolidine. MS/MS analysis of M2 produced fragment ions
at m/z 178 and 84, suggesting that oxygenation occurred at the
benzoimidazole carboxamide.
M3 and M4. M3 and M4 had the same protonated molecular ion at
m/z 277, eluting at approximately 22 and 30 min by HPLC analysis of
bile, plasma, and urine from rat and dog, respectively. High-resolution
MS analysis suggested additions of two oxygen atoms (32 amu) to
veliparib. MS/MS analysis of M3 showed fragment ions at m/z 259
and 162, suggesting that modification occurred at the 2-methylpyrro-
lidine moiety. MS3 analysis of ion m/z 259 gave fragment ions of m/z
242, 225, 162, and 145. The ion at m/z 225 resulted from loss of two
NH3 (34 amu) from the ion at m/z 259, suggesting that M3 was an
amino acid metabolite. 1D and 2D NMR analysis of M3 samples
isolated from dog urine confirmed the proposed structure of amino
acid. 1H NMR (500 MHz, D2O)  7.80 (d, J  7.6 Hz, 1H), 7.75 (d,
J  8.0 Hz, 1H), 7.36 (t, J  7.9 Hz, 1H), 2.31–2.24 (m, 2H), 2.05
(td, J  7.3, 2.5 Hz, 2H), 1.73 (s, 3H). MS/MS analysis of M4 showed
fragment ions at m/z 260, 259, 249, 232, 202, and 162. The presence
of a fragment ion at m/z 162 suggested that modification occurred at
the 2-methylpyrrolidine moiety.
M5 and M6. M5 was observed at approximately 19 min by HPLC
analysis of bile from rat and dog and dog plasma, and M6 was
observed at approximately 23 min only in rat bile. Both M5 and M6
had a protonated molecular ion of m/z 437. High-resolution MS
indicated additions of one oxygen atom (16 amu) and a glucuronic
acid (176 amu) to afford a net gain of 192 amu compared with
veliparib. MS/MS fragmentation of M5 and M6 generated a common
fragment ion of m/z 261, suggesting that M5 and M6 were formed
through oxidation and glucuronidation of parent drug. MS/MS anal-
ysis of M5 produced a fragment ion of m/z 354, which resulted from
cleavage of 2-methylpyrrolidine, indicating that modification oc-
curred at the benzoimidazole carboxamide. An additional ion of m/z
178 confirmed the modification site at the benzoimidazole carboxam-
ide. MS/MS analysis of M6 generated fragment ions of m/z 276 and
162, indicating that modification occurred at the 2-methylpyrrolidine
moiety.
M7 and M8. M7 and M8 eluted at approximately 33 and 37 min
by HPLC analysis, respectively, displaying a protonated molecular
ion at m/z 259. High-resolution MS indicated addition of one
oxygen atom (16 amu) and loss of two hydrogens (2 amu)
compared with veliparib. MS/MS fragmentation of M7 resulted in
fragment ions at m/z 242, 224, 214, 197, 162, and 145. The ions of
m/z 162 and 145 suggested modification at 2-methylpyrrolidine.
MS/MS fragmentation of M8 generated fragment ions at m/z 242,
162, and 98, indicating that M8 was formed from modification at
2-methylpyrrolidine. The lactam structure of M8 was confirmed by
comparisons of the HPLC retention time and MS spectrum with
those of a synthetic standard.
M9. M9 eluted at approximately 38 min by HPLC analysis of bile
and plasma from rat and dog, showing a protonated molecular ion at
m/z 465, 220 amu greater than the molecular ion of veliparib. MS/MS
analysis of M9 generated fragment ions at m/z 289, 245, 162, and 145,
suggesting that M9 was a carbamoyl glucuronide with modification
occurring at 2-methylpyrrolidine.
M10 and M11. Both M10 and M11 had a protonated molecular ion
at m/z 451. M10 was only observed in rat bile with a HPLC retention
time of approximately 27 min, and M11 was eluted at approximately
26 min during HPLC analysis of bile from both rat and dog. High-
resolution MS analysis suggested additions of two oxygen atoms
(32 amu) and a glucuronic acid (176 amu) as well as loss of two
hydrogens (2 amu) to afford a net gain of 206 amu compared with
veliparib. MS/MS analysis of M10 showed fragment ions at m/z 275,
258, 162, and 145. The ions at m/z 162 and 145 indicated that
modification occurred at the 2-methylpyrrolidine. The fragment ion of
m/z 275 resulted from facile loss of a glucuronic acid (176 amu) and
was 16 amu greater than molecular ion of M8, suggesting that M10
may be formed from M8 through sequential oxidation and glucuroni-
dation at 2-methylpyrrolidine. MS/MS analysis of M11 showed frag-
ment ions at m/z 434, 275, 258, 178, and 161. The ion at m/z 178
indicated that modification occurred at benzoimidazole carboxamide.
The same fragment ion of m/z 275 suggested that M11 may be formed
from M8 through sequential oxidation and glucuronidation at the
benzoimidazole carboxamide.
Mass spectrometric characterization of veliparib and its metabolites
is shown in Table 1. The proposed biotransformation pathway of
veliparib in rats and dogs is shown in Fig. 2.
Absorption and Excretion of [3H]Veliparib in Rats and Dogs.
Mean total recovery of radioactivity after 72 h was 95.7% in rats and
91.3% in dog for intravenous administration and 97.6% in rats and
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84.3% in dog for oral administration (Table 2). In both species, the
dose of radioactivity was well absorbed and rapidly excreted in urine,
with minimal radioactivity excreted in bile and feces. In rats given a
5 mg/kg intravenous dose of [3H]veliparib, mean total radioactivity
recovery in 72 h was 79.4% of dose in urine and 	5% in bile or feces
(Table 2). For oral administration, total dose recovery in 72 h was
82.7% in urine, with 5.1% of the dose recovered in bile and 4.1% in
feces (Table 2). A nearly identical excretion profile was also observed
in dogs after an intravenous or oral dose of 2.5 mg/kg (Table 2).
Urinary elimination of radioactivity was rapid with greater than 70%
of the dose excreted within 24 h in both rats and dogs. The sum of
radioactivity doses recovered in urine and bile from orally treated
animals indicates that at least 87.8% of the dose was absorbed in rats
and 75.9% of the dose was absorbed in dog.
Metabolism of [3H]Veliparib in Rats. Veliparib was primarily
excreted in rat urine as parent drug. Radioactivity profiles in the 0 to
24 h urine collected from the intravenously dosed group showed that
approximately 53.3% of the dose was recovered as parent drug. In the
0 to 6 h bile, total radioactivity recovery was only 4.1% of the dose,
of which parent drug accounted for 0.6% (Table 3). A total of 10
metabolites (M1–M5, and M7–M11) were characterized in rat urine
and bile. The most significant metabolite was the lactam M8, repre-
senting approximately 21.5% of the dose (19.6% in urine and 1.9% in
bile). Other metabolites were minor, each representing 	3% of the
dose (Table 3). Similar metabolism and elimination patterns were
observed after a single 5 mg/kg oral dose of [3H]veliparib to rats.
Parent drug accounted for approximately 55.4% of the dose in the 0 to
24 h urine and 0.6% of the dose in the 0 to 6 h bile. The major metabolite,
M8, represented 23.7% of the dose (21.5% in urine and 2.2% in bile).
Other minor metabolites accounted for 	3% of the dose (Table 3).
After a 5 mg/kg intravenous dose of [3H]veliparib to rats, parent
drug was the most significant radiolabeled component in the circula-
FIG. 2. Proposed biotransformation pathway of veliparib in rats and dogs.
TABLE 1
Mass spectrometric characterization of veliparib and its metabolites in plasma, bile, or urine from rats and dogs
Identification M  H Proposed Formula Fragment Ions (m/z) Biotransformation Matrix
Veliparib 245 C13H16N4O MS
2: 84, 145, 162 Bile, urine, plasma (R, D)
M1 261 C13H16N4O2 MS
2: 100, 162, 216 Monooxidation Urine (R, D), plasma (D)
M2 261 C13H16N4O2 MS
2: 84, 178, 216 Monooxidation Urine, plasma (R, D)
M3 277 C13H16N4O3 MS
2: 162, 259
MS3 of m/z 259: 98, 145, 162, 242
Pyrrolidine ring-opening Bile, urine, plasma (R, D)
M4 277 C13H16N4O3 MS
2: 162, 202, 232, 249, 259, 260 Dioxidation or pyrrolidine ring-opening Bile, urine, plasma (R, D)
M5 437 C19H24N4O8 MS
2: 161, 178, 261, 337, 354 Oxidation  glucuronidation Bile (R, D), plasma (D)
M6 437 C19H24N4O8 MS
2: 145, 162, 209, 226, Oxidation  glucuronidation Bile (R)
M7 259 C13H14N4O2 MS
2: 98, 145, 162, 197, 214, 224, 242 Oxidation  dehydrogenation Bile, urine, plasma (R, D)
M8 259 C13H14N4O2 MS
2: 98, 162, 242 Lactam formation Bile, urine, plasma (R, D)
M9 465 C20H24N4O9 MS
2: 145, 162, 245, 289 Carbamoyl glucuronidation Bile, plasma (R, D)
M10 451 C19H22N4O9 MS
2: 145, 162, 258, 275 M8  oxidation  glucuronidation Bile (R)
M11 451 C19H22N4O9 MS
2: 161, 178, 258, 275, 434 M8  oxidation  glucuronidation Bile (R, D)
R, rat; D, dog.
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tion, representing 30.7 to 58.0% of the total plasma radioactivity at
0.5, 1, 2, or 4 h postdose (Fig. 3). M2 and M8 were two major
metabolites in circulation, representing 13.8 to 28.8% and 12.0 to
23.6% of the total plasma radioactivity, respectively. M3, M4, M7,
and M9 were identified as minor metabolites, with each representing
	10% of total plasma radioactivity (Fig. 3).
Metabolism of [3H]Veliparib in Dogs. Similar to that in rats, the
urine metabolite profile from the intravenously dosed dog showed that
approximately 44.0% of the dose was excreted as unchanged parent
drug within 24 h. Veliparib was not observed in dog bile. A total of
10 metabolites (M1–M9 and M11) were identified. M3 and M8 were
two significant metabolites in excreta, representing a total of 11.8 and
15.8% of the dose, respectively (Table 3). The majority of M3 and M8
was excreted in urine, representing 11.3 and 15.0% of the dose,
respectively. Other metabolites were minor, each accounting for less
than 3% of the dose. In circulation, the parent drug was the major
radiolabeled component at each sampling time point. The area under
the curve (AUC) of the concentration-time profile within 0 and 8 h
was estimated by using WinNonlin software (version 4.0; Pharsight,
Mountain View, CA). M2, M3, and M8 were identified as three major
metabolites, with AUC0–8 values that were estimated to be 19.3, 21.3,
and 28.8% of the veliparib AUC0–8, respectively. Minor metabolites
M4, M5, M7, and M9 were present, with each having an estimated
AUC0–8 	10% of the veliparib AUC0–8.
Similar excretion and metabolism profiles were observed in the
orally treated dog. Within 24 h, approximately 41.1% of the dose was
recovered as parent drug in urine, with M3 and M8 accounting for an
additional 11.2 and 17.9% of the dose, respectively (Table 3). In the
0 to 6 h bile, total radioactivity recovery was only 0.9%, and no parent
drug was observed. Parent drug was the major radiolabeled compo-
nent in dog plasma at each time point (Fig. 4). M2, M3, and M8 were
three major metabolites, with estimated AUC0–8 values representing
27.3, 38.5, and 47.8% of parent AUC0–8, respectively (Fig. 4). Other
minor metabolites were M4, M5, M7, and M9 (each 	10% of parent
AUC0–8) (Fig. 3).
Tissue Distribution of Radioactivity in Rats. After a 5 mg/kg
intravenous dose of [3H]veliparib to rats, the distribution of [3H]ve-
liparib was extensive with radioactivity quantifiable in all tissues
examined. High tissue/plasma (T/P) ratios were observed in most of
the tissues (T/P ratio at 30-min postdose): kidney (5.3), liver (5.0),
bone marrow (4.6), lungs (2.9), spleen (3.1), thymus (2.7), muscle
(2.2), bone (1.6), skin (1.6), and heart (1.5), whereas lower T/P ratios
were observed in testes (0.6), brain (0.3), white fat (0.3), and spinal
cord (0.2) (Supplemental Table 1). The highest maximal concentra-
tions (nanogram equivalents of [3H]veliparib per gram) were found in
the kidneys (9537; 30 min), followed by liver (8966; 30 min) and bone
marrow (8222; 30 min) (Supplemental Table 1; Fig. 1). Maximal
radioactivity concentrations were observed 30 min postdose in all
TABLE 3
Distribution of veliparib and its metabolites in urine and bile from rats and dogs
Data are expressed as percentage of dose. Bold type indicates major excretory metabolites.
Rat (5 mg/kg) Dog (2.5 mg/kg)
Urine Bile Urine Bile
i.v., 0–24 h p.o., 0–24 h i.v., 0–6 h p.o., 0–6 h i.v., 0–24 h p.o., 0–24 h i.v., 0–6 h p.o., 0–6 h
M1 N.D. N.D. N.D. N.D. 1.5 0.7 N.D. N.D.
M2 N.D. N.D. N.D. N.D. 2.2 1.2 N.D. N.D.
M3 1.6 1.7 0.5 0.3 11.3 11.2 0.5 0.3
M4 2.4 2.5 0.1 0.1 1.5 0.8 MS MS
M5 N.D. N.D. 0.4 0.4 N.D. N.D. 0.2 0.1
M6 N.D. N.D. N.D. N.D. N.D. N.D. 0.1 0.1
M7 2.4 1.7 0.04 N.D. 1.2 1.2 MS MS
M8 19.6 21.5 1.9 2.2 15.0 17.9 0.8 0.3
M9 N.D. N.D. 0.5 0.9 N.D. N.D. 0.2 0.04
M10 N.D. N.D. 0.1 0.1 N.D. N.D. N.D. N.D.
M11 N.D. N.D. 0.1 0.1 N.D. N.D. N.D. N.D.
Veliparib 53.3 55.4 0.6 0.6 44 41.1 N.D. N.D.
Othersa N.D. N.D. N.D. N.D. N.D. N.D. 0.2 0.1
Total recoveryb 78.4 82.7 4.1 4.6 76.7 74.0 0.1 0.9
N.D., not detected; MS, detected by MS.
a Unidentified components.
b Total dose recovery is calculated from the sum of all quantifiable metabolites.
TABLE 2
Cumulative recovery of radioactivity in urine, feces, cage wash, and bile after a 5 mg/kg i.v. or oral dose to BDC rats and a 2.5 mg/kg i.v. or oral dose to BDC dogs
Rat data are presented as the mean  S.D.
Animal Route Dose Animal (n)
Recovery of Radioactivity
Time Point Urine Bile Feces Cage Wash Total Recovery
mg/kg h % dose
Rats i.v. 5 3 0–24 78.4  7.0 4.5  0.7 3.0  1.2 N.S. 85.9  5.1
0–72 79.3  6.3 4.7  0.7 3.7  1.0 8.0  3.1 95.7  2.1
p.o. 5 3 0–24 82.0  8.8 4.9  1.2 3.7  1.0 N.S. 90.6  6.6
0–72 82.7  8.4 5.1  1.2 4.1  1.1 5.7  5.0 97.6  1.2
Dogs i.v. 2.5 1 0–24 76.7 2.4 0.9 0.9 80.9
0–72 83.7 2.4 3.8 1.4 91.3
p.o. 2.5 1 0–24 71.8 1.9 4.1 2.7 80.5
0–72 74 1.9 4.9 3.5 84.3
BDC, bile duct-cannulated; N.S., no sample.
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tissues, and the concentrations declined with time. After 48 h post-
dose, less than 80 ng-Eq of [3H]veliparib/g radioactivity remained in
any of the selected tissues. T/P ratios generally decreased or remained
unchanged for most tissues.
Interactions of Veliparib with Human P-gp. Permeability and
transport of veliparib were evaluated in triplicate in both MDR1-
MDCK and wild-type MDCK cell monolayers at 1 M to investigate
whether veliparib is a substrate for human P-gp (MDR1). Veliparib
had high apparent apical-to-basolateral permeability values of 8.2 
1.0  106 cm/s in wild-type MDCK cells and 13.4  2.1  106
cm/s in MDR1-MDCK cells. The efflux ratio was 1.0 in wild-type
MDCK cells and 1.8 in MDR1-MDCK cells. The net flux ratio of
veliparib in MDR1-MDCK cells was calculated to be 1.8, suggesting
that veliparib was a weak substrate for human P-gp. Quinidine,
ranitidine, and talinolol are known P-gp substrates and were used as
positive controls in the assay, showing net flux ratios of 3.9, 2.9, and
10.7 in MDR1-MDCK cells, respectively. Recoveries of test articles
were high (88%).
The inhibition potential of veliparib on human P-gp activity was
evaluated in a Caco-2 monolayer using digoxin as the probe P-gp
substrate at veliparib concentrations of 0 to 100 M in the first study
and at 1000 M in a second study. The efflux ratio of 9.2 for digoxin
transport in Caco-2 cells was observed in the first study, and this
efflux in digoxin transport was completely inhibited in the presence of
the P-gp inhibitor verapamil at 30 M (digoxin efflux ratio of 1.6). In
contrast, veliparib did not demonstrate significant inhibition of the
P-gp-dependent efflux of digoxin up to the highest tested concentra-
tion of 100 M (digoxin efflux ratios: 7.5–14.7). In a second study,
P-gp inhibition by veliparib was investigated in Caco-2 cells at the
FIG. 3. Representative plasma HPLC-radiochromatograms from
rats (0.5 h) receiving a 5 mg/kg intravenous dose and a dog (6 h)
receiving a 2.5 mg/kg oral dose of [3H]veliparib.
FIG. 4. Plasma concentration-time profiles of total radioactivity, unchanged veli-
parib, and major metabolites M2, M3, and M8 after a single oral administration of
2.5 mg/kg [3H]veliparib to a dog.
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veliparib concentration of 1000 M. An efflux ratio of 4.2 was
observed for digoxin transport, which was inhibited by 30 M vera-
pamil (digoxin efflux ratio of 1.4), but was not affected by 1000 M
veliparib (digoxin efflux ratio of 4.9).
Discussion
Veliparib, a novel PARP inhibitor being developed for treatment of
cancer, demonstrated high and rapid absorption. In bile duct-cannu-
lated rats and dogs, at least 87.8 and 75.9% of dosed radioactivity was
absorbed, respectively, consistent with high oral bioavailability
(60%) (Donawho et al., 2007). Likewise, high absorption of veli-
parib was indicated in humans by, on average, 70% of the dose being
recovered as parent drug in urine (Kummar et al., 2009). Veliparib
absorption was also rapid with Tmax ranging from 0.5 to 2.3 h in
animals and 0.5 to 1.5 h in humans after oral administration
(Donawho et al., 2007; Kummar et al., 2009).
Renal secretion is the primary route of veliparib clearance. In bile
duct-cannulated rats and dogs, drug-related materials were primarily
eliminated in urine, with a significant portion as parent drug (40%
of dose). In humans, approximately 70% of the dose was consistently
excreted in urine as parent drug. An in vitro study demonstrated that
veliparib is a substrate for human organic cation transporter 2 (OCT2),
a renal transporter involved in active secretion of cationic drugs (R.
Kikuchi, Y. Lao, D. Bow, R. Voorman, and S. de Morais, manuscript
in preparation). Both in vivo excretion profiles and in vitro transporter
data suggest the involvement of active renal secretion and support the
conclusion that renal clearance is the primary mechanism of veliparib
clearance. The excretion profile of veliparib is similar to that of
varenicline, which is also primarily excreted as the parent drug in
urine of animals and humans and is an OCT2 substrate (Obach et al.,
2006; Feng et al., 2008). In a clinical DDI study with cimetidine, an
OCT2 inhibitor, a small increase in varenicline exposure was ob-
served (Feng et al., 2008). A moderate increase in varenicline expo-
sure was also observed in patients with renal impairment (Obach et
al., 2006). Given the similarity of clearance mechanisms between
veliparib and varenicline, veliparib exposure could be altered with
concomitantly administered cimetidine or in patients with renal im-
pairment. The clinical significance of these potential interactions may
need further evaluation.
Metabolism plays a secondary role in veliparib clearance. In excreta
of animals, metabolites contributed up to 33% the dose. A total of 11
metabolites were characterized. The lactam M8 was the most signif-
icant metabolite in both species, accounting for 15 to 24% of the dose.
The amino acid metabolite M3 represented an additional approxi-
mately 11% of the dose in dogs. In circulation, M8 and monooxy-
genated metabolite M2 were two major metabolites in rats and dogs.
M3 was another major circulatory metabolite in dogs. Consistent with
animal plasma profiles, M8 was a major plasma metabolite in patients
receiving veliparib (Wiegand et al., 2010). M8 was approximately
5-fold less potent than veliparib for in vitro PARP inhibition (Ki 23
nM) (Penning et al., 2009). A radiolabeled mass balance study has not
been conducted in humans, and radioactivity profiles of human
plasma and urine are unknown. Metabolite profiling studies with
nonradiolabeled human plasma samples suggested that the prelimi-
nary metabolite profile was similar to those in rats and dogs. Parent
drug was the major component, and three metabolites were charac-
terized including M8 as a major metabolite and two minor metabo-
lites, M2 and M9 (N-carbamoyl glucuronide) (X. Li and Y. Lao,
unpublished data).
Veliparib metabolism mainly occurred on the pyrrolidine to gener-
ate lactam, amino acid, N-carbamoyl glucuronide, and products of
monooxygenation and oxidation followed by dehydrogenation. Addi-
tional monooxygenation occurred on the benzoimidazole carboxam-
ide. Other secondary glucuronide metabolites were formed from the
above primary metabolites. Pyrrolidine is well known to be metabo-
lized to form lactam via either iminium ions or carbinolamines (Vick-
ers and Polsky, 2000). The amino acid metabolite is not believed to
be formed from lactam hydrolysis; rather it is proposed to arise from
the amino aldehydes that may be produced from ring opening of
unstable carbinolamine intermediates (Vickers and Polsky, 2000).
Multiple recombinant human P450s including CYP2D6, 1A2, 2C19,
and 3A4 demonstrated the ability to metabolize veliparib to generate
M2 and M8.
Veliparib demonstrated wide tissue distribution and crossed the
blood-brain barrier (BBB) in rats. After a single intravenous dose of
[3H]veliparib to rat, the dosed radioactivity was distributed widely to
all selected tissues, consistent with the high volume of distribution
(3.1 l/kg) observed in the rat pharmacokinetics profile. The highest
radioactivity concentrations were observed in kidneys, consistent with
the predominant urinary excretion of drug-related radioactivity. Drug-
related radioactivity was observed in brain, with the brain/ plasma
(B/P) radioactivity concentration ratio ranging from 0.3 to 1, indicat-
ing moderate brain penetration. The data are consistent with previous
results for central nervous system penetration in mouse, rat, and
monkey, in which veliparib demonstrated a B/P ratio of approximately
1:3 in rats and mice and cerebrospinal fluid penetration of approxi-
mately 57% in monkey (Donawho et al., 2007; Penning et al., 2009;
Muscal et al., 2010). Because human P-gp in the BBB is primarily
responsible for limiting the entry of drugs into the brain, it is impor-
tant to determine whether veliparib is a substrate for human P-gp. A
previous study reported a good B/P ratio of 0.98 in wild-type mice
treated with a single intravenous dose of 10 mg/kg veliparib. The B/P
ratio increased in mdr1a/1b double knockout (KO) (4.5), bcrp KO
(1.5), or triple KO mice (7.5), indicating that brain penetration of
veliparib was affected by P-gp and breast cancer resistance protein
(Fan et al., 2010). Consistently in our study, veliparib was shown to
be a weak substrate for P-gp with a low net flux ratio of 1.8 in
MDR1-MDCK cells. A net flux ratio of more than 2 is considered a
positive result for a P-gp substrate (U.S. Food and Drug Administra-
tion, 2006). Although veliparib is a weak substrate for P-gp and its
brain penetration was affected by P-gp, because of its high permea-
bility, veliparib could still penetrate through the BBB via passive
diffusion to achieve sufficient exposure. This result is consistent with
the finding that veliparib in combination with TMZ demonstrated
efficacy in a preclinical brain tumor model (Donawho et al., 2007).
Veliparib is being investigated in clinical trials in patients with brain
and central nervous system tumors (http://www.clinicaltrials.gov).
P-gp has also been reported to cause clinically significant DDIs via
P-gp inhibition or induction, i.e., digoxin-verapamil and digoxin-
rifampicin (Marchetti et al., 2007). A number of anticancer chemo-
therapeutic agents such as paclitaxel, doxorubicin, and topotecan are
known P-gp substrates and are being coadministered with veliparib.
To further characterize the potential DDIs of veliparib with these P-gp
substrates, we evaluated whether veliparib inhibits P-gp activity using
digoxin as a probe substrate in Caco-2 cells. Our study demonstrated
that veliparib did not inhibit P-gp-mediated digoxin transport up to
1000 M. The projected clinically efficacious dose of veliparib in
combination with TMZ is 40 mg twice a day. The intestinal concen-
tration of veliparib is estimated to be approximately 650 M, at which
veliparib is not expected to inhibit P-gp activity in the intestine. A
good in vitro-in vivo correlation was established for varenciline.
Varenciline did not have a clinically relevant effect on digoxin expo-
sure in vivo, supported by in vitro studies that varenicline was neither
a P-gp substrate nor an inhibitor of P-gp-mediated efflux of digoxin in
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Caco-2 cells (Faessel et al., 2008). Overall, veliparib would not be
expected to have clinically significant P-gp-mediated DDIs.
In addition, veliparib is not likely to cause clinically significant
DDIs mediated by P450s. Veliparib was metabolized in vitro by
multiple recombinant human P450s including CYP1A2, 2D6*1,
2C19, and 3A4. The highest turnover was observed with CYP2D6*1,
consistent with a previous study, in which CYP2D6 was shown to be
the predominant enzyme for veliparib metabolism (Li et al., 2009).
Common allelic variants CYP2D*10 and *4 showed reduced cata-
lytic activities, compared with wild-type CYP2D6, indicating that
CYP2D6 pharmacogenetics may affect veliparib pharmacokinetics
and efficacy in clinical studies (Li et al., 2009). CYP2D6 polymor-
phism has been associated with clinically relevant DDIs when drugs
significantly rely on the enzyme either for clearance or metabolism to
an active metabolite (de Groot et al., 2009). However, in humans, 70%
of the veliparib dose, on average, was excreted in urine as parent; thus,
metabolism contributed to at most 30% of total clearance. In addition,
veliparib was metabolized by multiple pathways including oxidation
catalyzed by other P450s and UGT-mediated N-carbamoyl glucuroni-
dation. The contribution of CYP2D6 to total veliparib clearance may
not be significant in humans. Therefore, CYP2D6 polymorphism or
coadministration of veliparib with CYP2D6 inhibitors would not
cause clinically significant DDIs. In addition, veliparib did not inhibit
activities of CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 2B6, 2C8, and 3A4
in human liver microsomes (IC50  30 M) or induce the activities of
CYP1A2, 2B6, 2C9, and 3A4 in human hepatocytes up to 10 M
(data not shown). Those concentrations obtained in in vitro evalua-
tions are much greater than the projected efficacious plasma concen-
tration of 0.78 M in clinics.
In summary, veliparib disposition was characterized by high ab-
sorption, wide tissue distribution, and primary renal clearance fol-
lowed by metabolic clearance. In urine and plasma, the major drug-
related component was unchanged veliparib. Veliparib is not likely to
cause clinically relevant DDIs mediated by P-gp and P450s. Taken
together, these attributes point to favorable dispositional and DDI
profiles, the desirable characteristics for a safe and effective thera-
peutic agent.
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